Johnson & Johnson (JNJ) : Advisor Partners reduced its stake in Johnson & Johnson by 14.43% during the most recent quarter end. The investment management company now holds a total of 44,084 shares of Johnson & Johnson which is valued at $5 Million after selling 7,434 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on May 11, 2016.Johnson & Johnson makes up approximately 1.87% of Advisor Partners’s portfolio.
Other Hedge Funds, Including , Novare Capital Management reduced its stake in JNJ by selling 5,587 shares or 8.84% in the most recent quarter. The Hedge Fund company now holds 57,615 shares of JNJ which is valued at $6.5 Million. Johnson & Johnson makes up approx 1.82% of Novare Capital Management’s portfolio.Alps Advisors Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 9,293 additional shares and now holds a total of 207,116 shares of Johnson & Johnson which is valued at $23.5 Million. Johnson & Johnson makes up approx 0.23% of Alps Advisors Inc’s portfolio.Integrated Wealth Counsel boosted its stake in JNJ in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 2,535 shares of Johnson & Johnson which is valued at $285,796. Johnson & Johnson makes up approx 0.64% of Integrated Wealth Counsel’s portfolio.
Johnson & Johnson opened for trading at $113.39 and hit $114.63 on the upside on Monday, eventually ending the session at $114.44, with a gain of 0.77% or 0.88 points. The heightened volatility saw the trading volume jump to 62,22,861 shares. Company has a market cap of $314,784 M.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Investors should note that on Apr 28, 2016, Johnson & Johnson announced a cash dividend of $0.8000. The company’s management has announced May 20, 2016 as the ex-dividend date and fixed the record date on May 24, 2016. The payable date has been fixed on Jun 7, 2016.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.